TransCode Therapeutics Announces Publication of New Data Supporting the Use of TTX-MC138 for the Treatment of Metastatic Breast Cancer

TransCode Therapeutics has announced new data supporting the use of TTX-MC138 for the treatment of metastatic breast cancer. The RNA oncology company's lead therapeutic candidate, TTX-MC138, is designed to inhibit microRNA-10b, described as the master regulator of cancer progression in a number of advanced solid tumors including breast cancer. In a preclinical model of pancreatic adenocarcinoma,..

  • format_list_bulleted BS
  • · 2023. 6. 26.
  • textsms

TransCode Therapeutics Announces Publication of New Data Supporting the Use of TTX-MC138 for the Treatment of Metastatic Breast Cancer

TransCode Therapeutics has published new data supporting the use of TTX-MC138 for the treatment of metastatic breast cancer. The lead therapeutic candidate, designed to inhibit microRNA-10b, has been shown to impair the capacity of cancer stem cells to create new tumors and become metastatic in breast cancer cells. Inhibiting these cells could improve outcomes in patients with recurrent and resi..

  • format_list_bulleted BS
  • · 2023. 6. 23.
  • textsms